gene
therapi
treatment
human
diseas
stage
intens
develop
alreadi
limit
use
experiment
therapi
cancer
oldfield
et
al
nabel
et
al
inborn
error
metabol
hoogerbrugg
et
al
morgan
anderson
becom
tool
treat
diseas
current
difficult
manag
mani
compet
strategi
develop
introduc
exogen
gene
subset
cell
patient
sever
like
proceed
clinic
applic
decid
therapeut
strategi
best
suit
given
diseas
requir
understand
underli
biolog
diseas
well
therapi
use
chapter
learn
liposom
method
gene
therapi
one
rememb
materi
present
current
januari
recent
develop
greater
detail
necessari
consult
origin
literatur
regardless
specif
diseas
address
gene
therapi
sever
factor
must
consid
one
treat
patient
first
method
treatment
must
commensur
sever
diseas
gene
therapi
prefer
treatment
diseas
phenylketonuria
galactosemia
treat
adequ
diet
modif
wide
recogn
problem
treatment
may
cure
diseas
creat
new
one
process
archetyp
concern
gener
insert
mutat
integr
cur
gene
cellular
protooncogen
lead
cancer
cure
patient
method
determin
reason
safe
patient
must
shown
present
danger
other
problem
hamper
widespread
use
viral
transfect
vector
substanti
progress
made
construct
replicationdefect
retrovir
adenovir
vector
howev
possibl
remain
superinfect
wildtyp
adenoviru
insert
wildtyp
retroviru
integr
defect
retrovir
genom
gener
new
infecti
viral
particl
could
contain
oncogen
fragment
therapeut
gene
viral
particl
may
abil
transfer
gene
patient
cell
individu
order
method
gene
therapi
use
must
significantli
amelior
symptom
diseas
halt
progress
diseas
state
signific
period
time
ideal
diseas
would
cure
perman
one
treatment
although
period
retreat
might
accept
everi
treatment
bring
possibl
insert
mutagenesi
gener
immun
respons
therapeut
vector
final
consider
involv
eas
prepar
use
mani
candid
vector
although
potenti
capabl
introduc
foreign
gene
organ
difficult
gener
administ
difficult
envis
widespread
adopt
aspect
vector
design
often
consid
vector
develop
bear
mind
consider
let
us
consid
variou
approach
develop
creat
vector
gene
therapi
gener
divid
three
group
activ
virus
ii
viral
mimic
attempt
reproduc
subset
viral
activ
synthet
construct
iii
artifici
deliveri
system
given
amount
effort
expend
develop
system
highli
vari
natur
intend
target
diseas
organ
like
never
singl
best
choic
method
everi
diseas
call
tailor
strategi
optim
best
fit
need
situat
tabl
contain
summari
comparison
variou
gene
therapi
deliveri
vector
ten
year
ago
seem
foregon
conclus
retrovirus
seriou
candid
eventu
therapeut
vector
today
mani
differ
viral
vector
consid
use
gene
therapi
differ
virus
target
differ
cell
type
differ
mode
replic
viral
deliveri
system
may
best
suit
treatment
differ
diseas
viral
vector
activ
develop
retrovirus
adenovirus
adenoassoci
viru
herpesvirus
gener
characterist
virus
current
develop
gene
therapi
vector
present
tabl
wildtyp
retrovirus
contain
within
lipid
membran
two
ident
copi
rna
genom
viral
particl
entri
cell
rna
molecul
reversetranscrib
dna
copi
integr
host
genom
mrna
variou
viral
protein
synthes
cours
infect
transcrib
integr
dna
integr
retrovir
dna
genom
host
genom
form
basi
use
retrovirus
vector
introduct
exogen
dna
eukaryot
cell
hoeben
et
al
convert
wildtyp
retroviru
retrovir
gene
therapi
vector
two
step
necessari
first
therapeut
gene
must
ad
retrovir
genom
second
potenti
retroviru
remain
infecti
integr
target
cell
must
elimin
present
accomplish
insert
therapeut
gene
retrovir
genom
gene
necessari
packag
viru
remov
mutat
delet
viral
gene
elimin
infect
treat
cell
prevent
newli
integr
genom
make
infecti
copi
could
complet
round
infect
also
ad
benefit
increas
maximum
length
therapeut
gene
deliv
retroviru
advantag
retrovirus
gene
deliveri
vector
includ
effici
stabl
integr
introduc
gene
host
genom
ii
wide
host
rang
iii
abil
infect
larg
number
cell
potenti
problem
associ
use
viral
vector
includ
possibl
recombin
event
could
convert
replicationdefect
vector
infecti
agent
ii
possibl
superinfect
anoth
retroviru
may
allow
unwant
transfer
introduc
gene
individu
iii
kb
limit
amount
dna
packag
iv
potenti
problem
target
viru
specif
cell
v
difficulti
maintain
highlevel
express
exogen
gene
wildtyp
adenovirus
caus
respiratori
diseas
human
adenoviru
genom
linear
doublestrand
dna
molecul
kb
length
although
viru
lipid
coat
taken
cell
via
endocytosi
enter
cytoplasm
manner
analog
retroviru
insid
cell
viral
dna
move
nucleu
begin
replic
cycl
without
becom
part
host
cell
genom
adenovirus
consid
use
gene
therapi
vector
substanti
part
genom
remov
render
unabl
replic
except
special
develop
cell
line
ie
packag
cell
line
express
remov
protein
kozarski
wilson
therapeut
gene
introduc
ad
adenovir
genom
homolog
recombin
plasmid
contain
therapeut
gene
flank
adenovir
dna
although
possibl
target
organ
adenovir
gene
therapi
includ
liver
central
nervou
system
vascular
endothelium
muscl
primari
target
organ
lung
clinic
trial
adenovir
gene
therapi
treatment
lantitrypsin
defici
cystic
fibrosi
underway
crystal
advantag
adenovirusbas
vector
includ
abil
infect
larg
number
cell
ii
rel
eas
construct
vector
obtain
larg
amount
viru
iii
absenc
genom
integr
obviat
problem
insert
mutagenesi
disadvantag
necess
period
reinfect
patient
genom
lost
divid
cell
ii
concomit
develop
allerg
respons
iii
possibl
toxic
high
dose
viru
adenoassoci
viru
natur
occur
defect
viru
infect
human
lung
although
unabl
go
lytic
infect
cell
independ
presenc
separ
infect
adenoviru
herp
simplex
viru
absenc
helper
infect
one
virus
adenoassoci
viru
establish
latent
infect
host
cell
integr
host
genom
integr
wildtyp
viru
occur
singl
site
chromosom
samulski
et
al
integr
seem
associ
diseas
viru
may
eventu
use
add
therapeut
gene
human
genom
lower
risk
insert
mutagenesi
date
howev
target
natur
insert
event
retain
nativ
viral
genom
replac
therapeut
marker
gene
addit
packag
constraint
limit
size
insert
kb
dna
genom
herpesvirus
larg
complex
fact
alon
might
argu
use
herp
simplex
viru
hsvi
gene
therapi
vector
sinc
complex
genom
difficult
effect
tame
howev
hsvi
advantag
compens
problem
viru
exist
mediat
persist
express
gene
neuron
postmitot
cell
geller
normal
cours
infect
hsvi
enter
neuron
cell
remain
latent
sometim
year
reactiv
start
lytic
cycl
result
small
patch
endotheli
cell
death
eg
cold
sore
latenc
host
cell
transcrib
viral
gene
produc
term
latenc
associ
transcript
lat
hsvi
delet
mutant
isol
incap
reactiv
insert
neuron
remain
latent
indefinit
therapeut
gene
ad
vector
lat
promot
element
express
even
though
viru
remain
latent
vector
develop
introduct
gene
cell
central
nervou
system
geller
summari
viral
method
gene
therapi
share
sever
strength
well
numer
weak
rel
easi
produc
larg
amount
viru
necessari
treat
patient
virus
effici
infect
larg
fraction
cell
come
contact
although
may
drawback
case
express
therapeut
gene
must
restrict
specif
cell
may
possibl
limit
unwant
express
insert
gene
use
tissuespecif
promot
viral
vector
human
gene
therapi
deriv
organ
caus
human
diseas
possibl
reactiv
vector
infect
pathogen
hard
dismiss
end
may
prove
easier
safer
construct
gene
therapi
vector
element
success
viru
deriv
complet
synthet
compon
one
strategi
involv
use
liposom
liposom
small
vesicl
usual
made
pure
prepar
phospholipid
made
complet
pure
compon
use
extens
character
defin
physic
properti
membran
membran
protein
liposom
also
use
mean
deliv
substanc
cell
vitro
vivo
includ
dna
hug
sleight
discuss
factor
consid
prepar
liposom
gene
therapi
given
diseas
worthwhil
review
gener
aspect
liposom
prepar
design
liposom
gener
classifi
number
bilay
lamella
contain
size
composit
membran
earliest
liposom
form
hydrat
dri
lipid
film
follow
vortex
result
cloudi
solut
liposom
mani
lamellar
layer
resembl
onion
call
multilamellar
vesicl
mlv
although
mlv
effect
packag
lipophil
drug
littl
aqueou
volum
interior
effici
entrap
watersolubl
compound
larg
dna
fragment
defici
mlv
quickli
supersed
unilamellar
vesicl
singl
lipid
bilay
extern
fluid
lumen
sever
method
use
prepar
unilamellar
vesicl
advantag
disadvantag
space
limit
briefli
describ
method
liposom
prepar
directli
relev
construct
gene
therapi
vector
tabl
give
direct
comparison
method
prepar
relat
transfect
cation
liposom
liposom
made
entir
partial
cation
lipid
chargebas
affin
dna
liposom
incub
solut
dna
form
complex
transfect
cell
sever
type
cation
lipid
avail
gener
similar
characterist
leventi
silviu
ito
et
al
gao
huang
hazinski
et
al
farhood
et
al
techniqu
initi
intend
exclus
vitro
use
howev
vivo
transfect
perform
sever
commerci
prepar
cation
lipid
sever
reason
cation
lipiddna
complex
prove
popular
transfect
easi
prepar
liposom
dna
incub
togeth
use
without
prepar
ii
complex
rel
nontox
iii
transfect
use
method
effici
cell
type
iv
dna
remain
outsid
liposom
question
entrap
effici
appli
vivo
transfect
use
cation
lipiddna
complex
complet
uncontrol
target
specif
bind
agent
present
complex
probabl
deliv
dna
first
cell
contact
occur
often
first
capillari
bed
inject
complex
pass
dnalipid
complex
intraven
inject
highest
level
gene
express
usual
seen
pulmonari
vascular
endothelium
brigham
et
al
dnalipid
complex
introduc
airway
caus
gener
transfect
lung
site
transfect
complet
uncontrol
express
insert
gene
may
need
regul
mean
tissuespecif
promot
hazinski
et
al
cell
specif
promot
avail
tissu
current
avail
sometim
less
specif
desir
cation
liposom
retrovir
gene
deliveri
vector
lack
abil
target
specif
cell
lack
length
constraint
make
tissuespecif
express
easier
achiev
use
dnalipid
complex
compar
retrovirus
edta
chelat
presenc
calcium
small
unilamellar
vesicl
suv
compos
acid
phospholipid
typic
phosphatidylserin
aggreg
fuse
larg
cochleat
structur
edta
ad
chelat
calcium
structur
form
larg
unilamellar
vesicl
luv
papahadjopoulo
et
al
process
vesicl
encapsul
substanti
fraction
surround
solvent
solut
dna
present
becom
encapsul
vesicl
two
advantag
techniqu
dna
expos
harsh
condit
would
degrad
ii
entrap
rel
effici
howev
requir
phosphatidylserin
make
techniqu
impract
vivo
applic
except
transfect
macrophag
cell
surfac
receptor
phosphatidylserin
ps
deterg
dialysi
virosom
membran
mix
deterg
concentr
critic
mix
micellar
concentr
cmmc
combin
membran
phospholipid
protein
form
mix
micel
deterg
rel
water
solubl
remov
mix
micel
dialysi
concentr
micel
fall
cmmc
membran
bilay
regener
form
liposom
envelop
virus
membran
protein
promot
fusion
viral
membran
cellular
membran
envelop
viru
fuse
cell
nucleocapsid
releas
cytoplasm
infect
proce
deterg
solubil
envelop
virus
produc
micellar
mixtur
contain
deterg
viral
phospholipid
viral
membran
protein
dialysi
deterg
mixtur
result
product
liposom
often
call
virosom
indic
presenc
viral
protein
dialysi
perform
properli
fusion
protein
mani
virus
reconstitut
activ
conform
white
et
al
viral
fusion
protein
varieti
differ
characterist
identifi
exampl
activ
low
ph
fuse
endosom
membran
other
activ
physiolog
ph
fuse
plasma
membran
viral
fusion
protein
ha
protein
influenza
bind
specif
receptor
fusion
viral
fusion
protein
promot
fusion
target
membran
contain
specif
mixtur
phospholipid
cervin
anderson
nussbaum
et
al
major
advantag
deterg
dialysi
gentl
sinc
sonic
vortex
organ
solvent
use
result
small
amount
dna
fragment
encapsul
unfortun
effici
entrap
low
caus
much
dna
wast
result
high
fraction
empti
liposom
form
loyter
cowork
fuse
dnacontain
liposom
cell
make
empti
virosom
dnacontain
liposom
separ
fuse
two
popul
vesicl
presenc
target
cell
lapidot
loyter
date
techniqu
use
vivo
reversephas
evapor
current
highest
dna
entrap
effici
achiev
vesicl
rev
prepar
reversephas
evapor
fraley
et
al
rev
prepar
bath
sonic
mixtur
lipid
dna
ether
buffer
salin
follow
evapor
ether
form
past
phospholipid
invert
monolay
surround
aqueou
droplet
resolv
liposom
vortex
past
encapsul
effici
high
small
amount
aqueou
buffer
present
relat
amount
lipid
presum
dna
molecul
present
buffer
forc
curl
small
aqueou
droplet
conform
easili
entrap
szelei
duda
size
distribut
rev
heterogen
hard
control
often
size
extrus
filter
use
extrus
multilamellar
vesicl
form
vortex
hydrat
lipid
film
repeatedli
pass
extrud
filter
pressur
liposom
forc
pore
filter
convert
multilamellar
unilamellar
vesicl
buffer
anyth
present
trap
insid
liposom
mayer
et
al
certain
extent
size
liposom
correspond
pore
size
filter
use
advantag
techniqu
nearli
lipid
lipid
mixtur
use
ii
liposom
size
nm
diamet
control
iii
encapsul
effici
excel
main
disadvantag
high
pressur
use
extrus
process
fragment
dna
denatur
dissoci
dnaprotein
complex
central
difficulti
use
liposom
gene
therapi
entrap
dna
ideal
encapsul
method
would
effici
entrap
degrad
dna
time
method
would
suffici
flexibl
regard
size
vesicl
composit
allow
target
liposom
base
properti
dna
solut
linear
conform
gener
dna
restrict
fragment
contain
entir
gene
much
longer
diamet
commonli
use
liposom
surpris
method
liposom
format
entrap
dna
low
effici
effici
invers
relat
length
dna
fraley
et
al
two
method
increas
entrap
effici
dna
develop
first
liposom
form
way
aqueou
phase
contain
dna
broken
droplet
small
enough
dna
forc
curl
upon
remain
within
droplet
probabl
occur
rev
format
method
achiev
result
complex
dna
substanc
tight
compact
aggreg
date
done
spermin
tikchonenko
et
al
basic
protein
jay
gilbert
effici
encapsul
also
increas
compact
dna
phage
head
particl
szelei
duda
liposom
entrap
basi
success
transfect
liposom
vector
deliv
intraven
lie
maxim
vivo
circul
time
liposom
liposom
formul
clear
rapidli
circul
reticuloendotheli
system
re
larg
amount
accumul
macrophag
allen
et
al
intend
target
gene
therapi
re
gaucher
diseas
benefit
case
howev
fate
serv
reduc
number
liposom
expos
intend
target
cell
popul
sever
differ
strategi
explor
lengthen
circul
halflif
liposom
certain
aspect
common
allen
et
al
gabizon
papahadjopoulo
first
seek
make
liposom
small
possibl
seem
reduc
interact
re
second
design
make
liposom
surfac
much
like
surfac
normal
cell
possibl
accomplish
use
lipid
formul
contain
high
fraction
cholesterol
high
transit
temperatur
phospholipid
substanti
fraction
sphingomyelin
gangliosid
gm
differ
approach
modifi
liposom
phospholipid
addit
polyethylen
glycol
peg
polar
headgroup
lasic
et
al
blume
cevc
pegmodifi
lipid
higher
hydrophil
nativ
lipid
appear
escap
recognit
macrophag
potenti
disadvantag
approach
target
liposom
coval
attach
antibodi
see
inhibit
presenc
pegmodifi
lipid
klibanov
et
al
liposom
formul
settl
upon
attent
must
paid
limit
number
cell
expos
dna
deliv
liposom
necessari
sever
reason
first
dna
integr
host
cell
genom
chanc
insert
mutagenesi
lead
activ
protooncogen
develop
cancer
host
limit
site
dna
deliveri
chanc
insert
mutagenesi
lower
second
limit
number
cell
transfect
reduc
amount
dna
lipid
protein
need
perform
gene
therapi
reduct
substanti
reduc
potenti
system
toxic
well
cost
tabl
compar
differ
method
target
liposom
specif
cell
type
three
gener
method
liposom
may
direct
subset
cell
within
organ
first
liposom
may
introduc
compart
bodi
sequest
gener
circul
one
exampl
addit
liposom
airway
fluid
aerosol
hazinski
et
al
stribl
et
al
liposom
cross
lung
epitheli
barrier
entranc
gener
circul
prevent
therefor
anticip
liposom
vector
transfect
cell
present
epitheli
surfac
anoth
site
approach
may
applic
central
nervou
system
cn
cerebr
vasculatur
blood
separ
cn
bloodbrain
barrier
would
normal
complet
imperm
liposom
howev
cerebr
vasculatur
isol
perfus
hyperosmot
solut
bloodbrain
barrier
damag
leav
hole
larg
enough
admit
liposom
cn
johansson
bloodbrain
barrier
reconstitut
shortli
thereaft
leav
liposom
trap
within
cn
unabl
interact
cell
may
specif
enough
second
lipid
composit
vesicl
adjust
caus
taken
preferenti
type
cell
exampl
macrophag
high
affin
liposom
contain
ps
surfac
lee
et
al
consequ
liposom
contain
substanti
fraction
ps
quickli
clear
circul
macrophag
allen
et
al
similar
target
strategi
use
lactosylceramid
membran
compon
lipid
bind
asialoglycoprotein
receptor
found
hepatocyt
caus
cell
preferenti
target
vesicl
gross
et
al
final
method
involv
addit
antibodi
protein
surfac
liposom
form
loughrey
et
al
proteoliposom
taken
cell
bind
tabl
give
repres
list
protein
use
target
liposom
cell
mani
protein
modifi
addit
phospholipid
molecul
acyl
chain
retain
nativ
function
modifi
protein
coupl
preexist
bilay
endow
liposom
bind
properti
three
method
describ
use
success
direct
uptak
liposom
specif
cell
type
method
mutual
exclus
principl
possibl
combin
specif
target
central
problem
liposomebas
gene
therapi
system
dna
must
introduc
cytoplasm
target
cell
dnaload
liposom
ad
cell
endocytos
carri
lysosom
degrad
digest
enzym
somehow
small
fraction
encapsul
dna
escap
pathway
enter
cytoplasm
express
cell
straubing
et
al
sever
method
develop
increas
proport
dna
deliv
cytosol
two
gener
approach
use
success
bypass
endocyt
pathway
complet
ii
use
initi
stage
endocyt
pathway
escap
pathway
deliveri
dna
lysosom
endocyt
pathway
liposom
dna
entri
cell
bypass
liposom
fuse
directli
plasma
membran
cell
accomplish
use
virosom
contain
constitut
activ
viral
fusion
protein
nakanishi
et
al
soon
virosom
bind
cell
surfac
fusion
protein
act
fuse
virosom
membran
cell
caus
vesicl
content
introduc
directli
cytoplasm
liposom
deliveri
system
use
initi
stage
endocyt
pathway
deliveri
process
strategi
take
advantag
low
ph
endosom
use
trigger
fusion
liposom
endosom
membran
phdepend
fusion
liposom
endosom
achiev
use
vesicl
compos
phosphatidylethanolamin
pe
substanc
dipalmitoylsuccinylglycerol
leav
membran
low
ph
liu
huang
ph
lower
endosom
effect
concentr
pe
rise
concentr
rise
mole
percent
vesicl
membran
longer
remain
bilay
convert
invert
hexagon
phase
destabil
adjac
endosom
membran
releas
liposom
content
cytoplasm
similar
result
seen
use
virosom
contain
phsensit
fusion
protein
gouldfogerit
et
al
lapidot
loyter
dna
success
introduc
cytoplasm
target
cell
factor
govern
express
much
less
well
understood
howev
protein
exist
karyophil
activ
transport
nucleu
two
protein
semliki
forest
viru
nucleocapsid
protein
michel
et
al
nonhiston
high
mobil
group
chromosom
protein
hmg
kato
et
al
tomita
et
al
gene
coencapsul
liposom
hmg
express
increas
much
level
seen
without
protein
deliveri
dnaprotein
complex
potenti
greatli
increas
transfect
effici
prove
compat
method
liposom
prepar
one
shortcom
present
approach
gene
therapi
share
inabl
maintain
high
level
express
transfect
gene
long
period
time
applic
activ
immun
system
fight
cancer
probabl
problem
howev
effect
cure
mani
genet
diseas
gene
need
express
near
normal
level
throughout
patient
life
success
transfect
cell
current
avail
viral
vector
may
lead
express
least
viral
protein
result
clearanc
cell
host
immun
system
process
may
partial
respons
loss
express
seen
transfect
retrovir
adenovir
vector
anoth
possibl
caus
low
level
express
length
constraint
viral
vector
usual
necessit
use
cdna
copi
gene
construct
intron
greatli
reduc
length
evid
transgen
mous
experi
express
exogen
gene
higher
least
intron
present
brinster
et
al
palmit
et
al
true
gene
insert
viral
liposom
method
may
necessari
includ
intron
deliv
dna
produc
adequ
therapeut
effect
unfortun
increas
size
therapeut
gene
would
prevent
use
viral
vector
method
gene
therapi
specif
advantag
none
suitabl
applic
environ
complex
live
organ
futil
hope
singl
method
might
ideal
situat
howev
avail
mani
method
greatli
increas
number
type
diseas
treat
virus
evolv
abl
effici
introduc
express
exogen
gene
ie
viral
gene
eukaryot
cell
howev
import
rememb
virus
optim
select
pressur
meet
criteria
precis
gene
therapi
particular
virus
need
maintain
highlevel
express
protein
short
time
need
concern
viabil
host
cell
infect
attempt
modifi
viru
gene
therapi
vector
hamper
conflict
virusbas
method
gene
therapi
like
use
applic
requir
burst
highlevel
express
mani
patient
cell
cancer
therapi
cation
lipiddna
complex
never
select
either
virusor
convent
liposomebas
gene
therapi
howev
remain
much
easier
prepar
use
complex
probabl
find
greatest
use
vitro
anim
gene
transfer
although
current
wide
use
area
gene
transfer
techniqu
lack
control
cellspecif
probabl
lead
replac
viral
liposom
method
gene
introduct
clinic
area
liposom
method
gene
therapi
flexibl
compon
system
control
design
system
becom
sophist
begun
take
sever
characterist
virus
intend
replac
use
basic
substanc
condens
dna
increas
effici
encapsul
addit
nucleophil
protein
rais
effici
transfect
ad
antibodi
target
molecul
surfac
liposom
preferenti
bind
vesicl
desir
cell
type
increas
incorpor
viral
fusion
protein
membran
allow
greater
fraction
liposom
bind
cell
deliv
content
cytoplasm
short
mani
aspect
viru
bud
deliveri
genet
materi
nucleu
mimick
liposom
vector
current
method
liposomebas
gene
therapi
may
improv
modifi
structur
introduc
gene
preliminari
indic
construct
resembl
nativ
gene
rather
cdna
provid
best
longterm
express
enhanc
basic
liposom
use
togeth
mutual
compat
howev
seem
inevit
best
liposomebas
gene
therapi
vector
eventu
combin
mani
enhanc
result
liposom
condens
dnaprotein
complex
contain
histonelik
protein
nuclear
target
protein
membran
design
long
circul
within
blood
target
molecul
surfac
viral
fusion
protein
membran
effect
complet
manmad
nonrepl
viru
